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Key messages
What is already known on this subject
 Ź PE is an important potential cause of morbidity 
in pregnancy but symptoms suggesting PE are 
common in pregnancy.
 Ź Recent studies suggest that a combination of 
clinical probability assessment and D- dimer 
measurement can allow safe discharge without 
imaging in a proportion of pregnant women 
with suspected PE.
What this study adds
 Ź This secondary analysis of the DiPEP study 
showed that strategies using clinical probability 
and D- dimer have limited diagnostic accuracy 
and do not accurately rule out all PE in 
pregnancy. It is uncertain whether PE missed 
by these strategies lead to clinically important 
consequences.
ABSTRACT
Objective Recent studies suggest that combinations of 
clinical probability assessment (the YEARS algorithm or 
Geneva score) and D- dimer can safely rule out suspected 
pulmonary embolism (PE) in pregnant women. We 
performed a secondary analysis of the DiPEP (Diagnosis 
of Pulmonary Embolism in Pregnancy) study data to 
determine the diagnostic accuracy of these strategies.
Methods The DiPEP study prospectively recruited 
and collected data and blood samples from pregnant/
postpartum women with suspected PE across 11 
hospitals and retrospectively collected data from 
pregnant/postpartum women with diagnosed PE across 
all UK hospitals (15 February 2015 to 31 August 2016). 
We selected prospectively recruited pregnant women 
who had deinitive diagnostic imaging for this analysis. 
We used clinical data and D- dimer results to determine 
whether the rule out strategies would recommend further 
investigation. Two independent adjudicators used data 
from imaging reports, treatments and adverse events up 
to 30 days to determine the reference standard.
Results PEs were diagnosed in 12/219 (5.5%) women. 
The YEARS/D- dimer strategy would have ruled out PE 
in 96/219 (43.8%) but this would have included 5 of 
the 12 with PEs. Sensitivity for PE was 58.3% (95% 
CI 28.6% to 83.5%) and speciicity 44.0% (37.1% to 
51.0%). The Geneva/D- dimer strategy would have ruled 
out PE in 46/219 (21.0%) but this would have included 
three of the 12 with PE. Sensitivity was 75.0% (95% CI 
42.8% to 93.3%) and speciicity 20.8% (95% CI 15.6% 
to 27.1%). Administration of anticoagulants prior to 
blood sampling may have reduced D- dimer sensitivity for 
small PE.
Conclusion Strategies using clinical probability and 
D- dimer have limited diagnostic accuracy and do not 
accurately rule out all PE in pregnancy. It is uncertain 
whether PE missed by these strategies lead to clinically 
important consequences.
INTRODUCTION
Recent studies suggest that combinations of clinical 
probability assessment and D- dimer can safely rule 
out pulmonary embolism (PE) in a proportion of 
pregnant women presenting with suspected PE who 
would otherwise require imaging to rule out PE. van 
der Pol et al1 tested a pregnancy- modified YEARS 
algorithm and D- dimer in 498 pregnant women 
with suspected PE presenting to 18 hospitals over 
5 years (20 with PE), ruling out PE without scan or 
adverse outcome in 195 (39%). Righini et al2 tested 
clinical probability scoring with the Geneva score 
alongside D- dimer in 395 pregnant women with 
suspected PE presenting to eleven hospitals over 8 
years (28 with PE), ruling out PE without scan or 
adverse outcome in 46 (12%).
These studies suggest that a proportion of women 
can avoid imaging for PE but may lack statistical 
power to ensure an acceptably low rate of adverse 
outcome in this group. The studies were designed 
to detect 3- month event rates of 2.7% and 3.0%, 
respectively, but it is unclear whether patients and 
clinicians consider these event rates acceptable for 
a potentially catastrophic outcome. We are not 
aware of any studies estimating clinician or patient 
willingness to accept risk of adverse outcome after 
discharge for suspected PE in pregnancy but a 
survey of emergency physicians reported that only 
18/1023 (1.8%) considered an adverse event rate 
above 2% acceptable following negative assessment 
for acute chest pain.3 Furthermore, the sample 
size was estimated and event rates reported across 
the entire cohort, including those who received 
imaging, whereas the relevant population is those 
who did not receive imaging. The upper 95% CI 
for the zero event rates in the non- imaged popu-
lation are 2.4% for the 195 women in the van der 
Pol study and 9.6% in the 46 women in the Righini 
study.
The DiPEP (Diagnosis of Pulmonary Embolism 
in Pregnancy) study prospectively recruited and 
collected data and blood samples from pregnant 
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and postpartum women with suspected PE across 11 sites, and 
retrospectively collected data from pregnant and postpartum 
women with diagnosed PE across the whole of the UK.4 5 Clin-
ical probability assessment and D- dimer were not routinely used 
to select women for investigation in the study and the relevant 
guidelines recommended against this practice.6 The DiPEP data, 
therefore, offered the opportunity to determine the diagnostic 
accuracy of rule out strategies, compared with a reference stan-
dard based on radiological imaging.
We aimed to undertake a secondary analysis of data and 
blood samples from pregnant women with suspected PE who 
were prospectively recruited to the DiPEP study, to determine 
the accuracy of rule out strategies based on clinical probability 
assessment and D- dimer.
METHODS
DiPEP was a prospective cohort study augmented with addi-
tional retrospective cases to determine whether clinical features, 
individually or in the form of a clinical decision rule, or D- dimer 
could be used to select pregnant and postpartum women for 
diagnostic imaging.4 It also involved analysis of blood samples 
collected from the prospective cohort to determine the accuracy 
of a range of biomarkers for PE in pregnancy and post partum.5
Prospectively recruited pregnant women with suspected PE 
were selected for this analysis. Women were identified at emer-
gency departments and maternity units across eleven sites over 
18 months and asked to provide written informed consent to 
data and blood sample collection. A research nurse or midwife 
then completed a case report form, including details of patient 
characteristics, investigations and treatments for venous throm-
boembolism (VTE). Hospital records were reviewed at 30 days 
after recruitment and any subsequent VTE- related investigations, 
treatments or adverse events were recorded. All management 
was at the discretion of the attending clinician and determined 
on the basis of patient need.
We excluded retrospectively identified women with diag-
nosed PE from this analysis because blood samples could not be 
collected from these women; and to prevent selection bias from 
incomplete retrospective case ascertainment, and avoid informa-
tion bias from retrospective data abstraction from case notes. 
Results of hospital D- dimer testing were available for some 
but different assays and thresholds for positivity were used in 
each hospital. Prospectively recruited postpartum women were 
excluded because neither of the rule out strategies had been 
developed or evaluated for postpartum women.
The pregnancy- adapted YEARS algorithm used three criteria 
to select women for D- dimer testing: clinical signs of deep vein 
thrombosis (DVT), haemoptysis and PE as the most likely diag-
nosis. The DiPEP case report form recorded whether haemop-
tysis was a presenting symptom, whether there were clinical 
signs of DVT and what was considered the most likely diagnosis 
after clinical assessment. These data were used to determine the 
results of applying the three criteria to DiPEP patients.
Righini et al2 used the revised Geneva score (low or interme-
diate pretest clinical probability) to select women for D- dimer 
testing. The DiPEP case report form recorded age, heart rate, 
whether haemoptysis was a presenting symptom any previous 
history of VTE, surgery or significant injury in the previous 
4 weeks, pre- existing cancer and clinical signs of DVT. A free- 
text box for recording any other symptoms was searched to iden-
tify patients presenting with unilateral lower limb pain. These 
data were used to determine the results of applying the revised 
Geneva score to DiPEP patients. We have previously evaluated a 
pregnancy- modified version of the revised Geneva score4 but for 
this analysis used an unmodified version to ensure consistency 
with the study of Righini et al.2
Serum and citrate blood samples were collected by a member 
of the clinical team or research nurse/midwife using good 
venepuncture technique, ideally while obtaining routine blood 
samples for standard clinical assessment in diagnostic workup. 
The samples were centrifuged at 2000 g for 15 min at room 
temperature and frozen down within 4 hours of being obtained. 
Citrate samples were further processed to obtain platelet free 
plasma.
Plasma and serum samples were stored in aliquots labelled 
with the patient ID and the storage box coordinates recorded 
on paper and electronic study documentation, according to local 
SURWRFROV7KHVDPSOHVZHUHVWRUHG LQï&IUHH]HUVDWHDFK
participating hospital (with the exception of one location where 
Dï&IUHH]HUZDVXVHGIRUWKHGXUDWLRQRQWKHVWXG\XQWLODOO
samples were transported for analysis to Guys St Thomas Trust, 
London, UK.
The Zymutest D- Dimer Eliza assay (Quadratech Diagnos-
tics, Epsom, UK) was used to measure the D- Dimers by ELISA 
according to the manufacturers instructions. The recommended 
threshold for the test was 400 ng/mL. The coefficient of variation 
was 4.6% intra- assay and 10.8% inter assay for the Zymutest 
D- Dimer. In accordance with the strategy of Righini et al, we 
used the recommended threshold of 400 ng/mL to rule out PE 
in women with a low or intermediate revised Geneva score. In 
accordance with the diagnostic strategy tested by van der Pol et 
al, we used the recommended threshold for positivity of 400 ng/
mL to rule out PE in women when one or more of the YEARS 
criteria and 800 ng/mL (double the recommended threshold for 
positivity) when none of the YEARS criteria were met.
The reference standard was determined by two independent 
observers, who reviewed reports of VTE- related diagnostic 
imaging, treatments and adverse events up to 30 days after 
recruitment. Any disagreements were settled by a third indepen-
dent expert. The reviewers were blinded to index test results.
In accordance with the primary analysis plan for DiPEP, this 
analysis was limited to those with conclusive imaging. This 
meant that the reference standard was effectively based on 
imaging results alone. A secondary analysis explored the effect 
of including those with inconclusive or no imaging. Analysis was 
descriptive, involving estimation of the sensitivity and specificity 
of each strategy for diagnosing PE, with a 95% CI.
Patient and public involvement
The DiPEP study steering committee included representatives 
from two patient organisations, Thombosis UK and the Sheffield 
Emergency Care Forum. They advised on the design, conduct 
and interpretation of the study, and assisted with dissemination 
of the findings.
RESULTS
A total of 324 women were recruited across 11 participating sites 
between 15 February 2015 and 31 August 2016. We excluded 55 
who were post partum and a further 9 who did not have D- dimer 
measurements recorded. The analysis was limited to 219 women 
with conclusive imaging (five were excluded with clinically diag-
nosed PE and 36 with clinically ruled out PE). Figure 1 shows 
the flow of participants through the study and table 1 outlines 
the characteristics of those included in the analysis.
PE was diagnosed in 12/219 (5.5%). Table 2 shows the 
maternal and gestational age for each woman with PE and how 
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Figure 1 Flow of participants through the study. PE, pulmonary 
embolism; CTPA, computed tomography pulmonary angiogram
Table 1 Characteristics of the study population
Characteristic Patients (n=219)
Mean age 29.3 years
Mean BMI 27.9 kg/m2
Mean heart rate 97.8/min
Mean respiratory rate 18.9/min
Mean oxygen saturation 97.8%
Mean systolic blood pressure 120.7 mm Hg
Mean diastolic blood pressure 71.9 mm Hg
Mean temperature 36.5°C
Smoking status
  Never 150 (68.5%)
  Gave up before 28 (12.8%)
  Gave up during 15 (6.8%)
  Current 26 (11.9%)
One or more previous pregnancies <24 weeks 86 (39.3%)
One or more previous pregnancy >24 weeks 137 (62.6%)
Family history of thrombosis 41 (18.7%)
History of varicose veins 18 (8.2%)
History of intravenous drug use 1 (0.5%)
Known thrombophilia 6 (2.7%)
Surgery in previous 4 weeks 1 (0.5%)
Signiicant injury in the previous 4 weeks 1 (0.5%)
History of thrombosis 17 (7.8%)
First trimester 20 (9.1%)
Second trimester 81 (37.0%)
Third trimester 118 (53.9%)
Multiple pregnancy 11 (5.0%)
Long- haul travel during pregnancy 20 (9.1%)
Three or more days of immobility/bed rest 13 (5.9%)
BMI, body mass index.
PE was diagnosed on imaging. The diagnosis was based on 
computed tomography pulmonary angiogram (CTPA) findings 
for five women, ventilation- perfusion scanning for six women, 
and lower limb ultrasound evidence of DVT in the presence of 
symptoms of PE for one woman.
Table 3 shows the results of applying the YEARS/D- dimer (van 
der Pol) strategy to this cohort and table 4 shows the results 
of applying Geneva/D- dimer (Righini) strategy. The YEARS/D- -
dimer strategy would have resulted in 96/219 women (43.8%) 
being discharged without imaging, but this would have included 
5/12 with PE. The sensitivity of the strategy was 58.3% (95% CI 
28.6% to 83.5%) and specificity was 44.0% (37.1% to 51.0%). 
The Geneva/D- dimer strategy would have resulted in 46/219 
women (21.0%) being discharged without scanning, but this 
would have included 3/12 with PE. The sensitivity of the strategy 
was 75.0% (42.8% to 93.3%) and specificity was 20.8% (15.6% 
to 27.1%).
Secondary analysis including those with inconclusive or no 
imaging produced similar results. The YEARS/D- dimer strategy 
sensitivity was 52.9% (28.5% to 76.1%) and specificity 42.4% 
(36.1% to 48.9%). The Geneva/D- dimer strategy sensitivity 
was 70.6% (44.1% to 88.6%) and specificity 19.8% (15.1% to 
25.4%).
Table 5 shows the elements of each strategy and whether the 
overall strategy indicated PE (requiring imaging) or no PE (no 
imaging required). The YEARS algorithm was positive in seven 
women and negative in five. The Geneva score was high in two 
women, intermediate in nine women and low in one. D- dimer 
was positive in eight women using the conventional threshold 
and positive in six women using a threshold double the conven-
tional threshold.
Table 5 also shows whether the women with PE received anti-
coagulation prior to blood sampling, as this may interfere with 
D- dimer measurement. Ten women received anticoagulation, 
ranging from 0 to 16 hours before sampling. One woman was 
recorded as having no anticoagulation prior to blood sampling 
but elsewhere was recorded as commencing thromboprophy-
laxis 3 months prior to presentation. It is therefore not clear 
whether her D- dimer result could have been influenced by anti-
coagulant treatment. One woman had no anticoagulation prior 
to blood sampling and, although PE was considered the most 
likely diagnosis and the Geneva score indicated intermediate risk 
of PE, both strategies indicated no PE on account of her negative 
D- dimer result (263 ng/mL).
DISCUSSION
Main findings
Our findings suggest that PE rule out strategies based on clin-
ical probability assessment and D- dimer do not reliably rule out 
all PE in pregnant women with suspected PE who would other-
wise require imaging. The YEARS/D- dimer strategy would have 
missed five of the 12 and the Geneva/D- dimer strategy would 
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Table 2 Characteristics of the women diagnosed with PE
Patient no Maternal age Gestational age Imaging method Imaging report
1 35 28/40 CTPA Segmental PE lower left lobe
2 34 37/40 VQ Isolated wedge shaped perfusion defect in the apical segment of the right lower lobe
3 26 36/40 CTPA Extensive bilateral PE
4 33 35/40 CTPA On balance of probability non- occlusive illing defect in the left upper lobe segmental 
vessel represents PE
5 26 23/40 VQ Perfusion defects in both lungs
6 33 24/40 VQ Extensive reduction of perfusion to the right lung with further segmental areas of 
perfusion loss in the left lung. The ventilation scan is almost normal.
7 26 32/40 US lower limb Echogenic thrombus demonstrated within the left common femoral vein, which 
extends down to the left popliteal vein. The vein was not patent and incompressible
8 21 29/40 CTPA Appearances are highly suspicious for solitary small PE
9 33 24/40 VQ Unmatched perfusion defect in the right mid to lower lung
10 32 27/40 VQ Appearances are in keeping with a right acute PE
11 25 15/40 VQ The segmental perfusion defect in the right lung posteriorly is mismatched with the 
ventilation images. Findings are in line with PE
12 34 13/40 CTPA Extensive bilateral pulmonary embolus
Table 3 Results of applying the YEARS/D- dimer strategy (N, %, 95% 
CI)
PE No PE Total
Strategy 
positive
7
58.3
28.6 to 83.5
116
56.0
49.0 to 62.9
123
56.2
49.3 to 62.8
Strategy 
negative
5
41.7
16.5 to 71.4
91
44.0
37.1 to 51.0
96
43.8
37.2 to 50.7
Total 12 207 219
PE, pulmonary embolism.
Table 4 Results of applying the Geneva/D- dimer strategy (N, %, 95% 
CI)
PE No PE Total
Strategy 
positive
9
75.0
42.8 to 93.3
164
79.2
72.9 to 84.4
173
79.0
72.9 to 84.1
Strategy 
negative
3
25.0
6.7 to 57.2
43
20.8
15.6 to 27.1
46
21.0
15.9 to 27.1
Total 12 207 219
PE, pulmonary embolism.
have missed three of the 12 women diagnosed with PE in the 
DiPEP study.
These findings appear to be inconsistent with the original 
studies of these algorithms, which identified no symptomatic 
VTE on follow- up of 46 women with negative assessment using 
the Geneva/D- dimer strategy and only one DVT on follow- up of 
195 women with negative assessment using the YEARS/D- dimer 
strategy. This apparent inconsistency may be explained by the 
different designs of the studies, both of which provide useful 
information and neither of which should be considered defini-
tive. DiPEP is a diagnostic accuracy study in which strategies are 
compared with an imaging reference standard. The Righini and 
van der Pol studies are management studies that estimate the risk 
of adverse outcome in women who have PE ruled out without 
imaging. Interpretation requires consideration of the strengths 
and limitations of both designs, and the consequences of missed 
PE.
The relatively low prevalence of PE in the Righini and van 
der Pol study cohorts means that even if the strategies missed a 
quarter of the cases of PE, this would only result in a few missed 
cases among those discharged without imaging or treatment. 
The outcomes of PE without treatment are difficult to estimate 
but it is conceivable that a small number of missed cases could 
occur without leading to serious adverse outcome. Similarly, the 
three and five women with PE in the DiPEP study who were 
respectively missed by the Geneva/D- dimer and YEARS/D- dimer 
strategies could have survived without adverse event if they had 
not been treated. A larger cohort of women receiving no treat-
ment after negative assessment would be required to determine 
whether missed cases led to an unacceptable rate of adverse 
outcome.
It is an interesting observation that when using the van der Pol 
and modified Geneva scores, the five missed PE were reported 
as small or segmental (see table 2). Moreover, these five had 
the lowest values of D- dimer. These two findings suggest that 
the volume of the emboli and/or lung tissue affected was small. 
Unfortunately, the techniques used to identify the PE cannot 
accurately assess the size of the thrombus and area of pulmo-
nary damage. These observations tentatively suggest that the two 
scores do detect large PE. However, ignoring small PE is not a 
safe strategy as these may be a harbinger of later large PE.
The inconsistency between our study and previous studies is 
unlikely to be explained by differences in the study populations. 
The study populations had a similar prevalence of PE. The two 
previous studies were prospective and our analysis was limited to 
prospectively recruited pregnant women with suspected PE. The 
two previous studies both recruited women who would other-
wise have received imaging (and the authors caution against 
extrapolating findings to other, lower risk, women) and our 
analysis was limited to those who received imaging. The van der 
Pol study described recruitment as consecutive, while the Righini 
and DiPEP studies did not. However, the recruitment rates 
across the studies suggested that the DiPEP population was not 
a more highly selected population, with 219 women recruited 
across eleven sites over 19 months, compared with 498 across 
18 sites over 56 months recruited by van der Pol et al and 395 
across eleven sites over 96 months recruited by Righini et al.
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Table 5 Application of the rule out strategies to women with PE
Patient Haemoptysis
Clinical signs 
DVT
PE most likely 
diagnosis
Geneva 
score D- dimer
Thrombo- 
prophylaxis
Anticoagulant (time 
before D- dimer)
YEARS/D- dimer 
strategy
Geneva/D- dimer 
strategy
1 No Yes No 12 708 No Dalteparin
7500 IU, 14 hours
PE PE
2 No No No 5 1469 No Dalteparin
6000 IU, 2 hour
PE PE
3 No No Yes 5 4802 Yes Tinzaparin
19 000 IU, 16 hours
PE PE
4 No No No 6 261 Yes No* No PE No PE
5 No No No 0 823 No Tinzaparin
175 u/kg, 0 hour
PE PE
6 No No No 5 1444 No Dalteparin
7500 IU, 4.5 hours
PE PE
7 No Yes Yes 9 2696 No Dalteparin
7500 IU, 7 hours
PE PE
8 No No No 5 662 No Dalteparin
10 000 IU, 7 hours
No PE PE
9 No Yes No 15 194 Yes Dalteparin
12 500 IU, 2 hours
No PE PE
10 Yes No No 5 265 Yes Enoxaparin
80 mg, 6.5 hours
No PE No PE
11 No No Yes 5 263 No No No PE No PE
12 No No Yes 5 4329 No Tinzaparin
18 000 IU, 13.5 hour
PE PE
*Recorded as receiving no anticoagulation before blood sampling, but also recorded as commencing tinazaparin 15 000 IU daily for thromboprophylaxis 3 months prior to 
presentation.
DVT, deep vein thrombosis ; PE, pulmonary embolism.
The DiPEP study had limitations that may explain the incon-
sistency with previous studies. Most women in the DiPEP study 
received anticoagulation prior to blood sampling. This reflects 
adherence to UK guidance7 that recommends immediate interim 
parenteral anticoagulant therapy if PE is suspected and imaging 
cannot be carried out immediately. The process of informing 
participants and acquiring consent in the DiPEP study meant 
that blood sampling could not be undertaken immediately. A 
pooled analysis by Couturaud et al8 estimated that 24 hours 
after starting heparin therapy D- dimer levels have decreased by 
25% in patients with acute VTE, while a more recent analysis by 
Baker and Keeling9 reported a mean decrease of 16% 12 hours 
after administration of low- molecular- weight heparin. This may 
have reduced the sensitivity of the strategies but the estimated 
reductions in D- dimer levels are insufficient to account for the 
false negative D- dimer results reported in table 4 and would 
not explain the false negative result in the patient who did not 
receive anticoagulation prior to blood sampling.
Another limitation of the DiPEP study is that the strategies 
were applied in theory but not in practice, and the assessment 
of PE probability was determined according to the documented 
diagnostic impression. This may be a source of bias if clinicians 
did not look for or record features such as unilateral lower limb 
pain, or if interpretation of the documented diagnostic impres-
sion is inaccurate. Furthermore, if clinicians are risk- averse, they 
may deviate from diagnostic protocols in a way that enhances 
sensitivity at the expense of specificity. For example, many 
clinicians would not be reassured by a negative D- dimer in the 
presence of a history of haemoptysis (patient 10) and would 
over- ride the diagnostic strategy and arrange imaging for PE in 
this case. The van der Pol and Righini studies have the advantage 
of showing what clinicians actually do in practice but may be 
undermined if clinicians exclude eligible patients from the study 
when they decide to over- ride the strategy.
The recruitment rates in these three studies raise concerns 
about whether the benefits of using clinical probability assessment 
and D- dimer to rule out PE are worth the risks. The recruitment 
rates suggest that less than five women per site per year would 
avoid imaging. The small cost savings and reduction in radiation 
risk associated with avoiding a small number of scans per year do 
not seem to justify the potentially catastrophic consequences of 
missing PE. For the fetus, the increased risk of childhood cancer 
to the age of 15 is 0.0006%, while for a mother with a typical 
background risk of developing breast cancer of 0.1% in the 
following 10 years, the absolute risk increase from 10 mGy of 
radiation is 0.0136%.1014 Decision analytical modelling under-
taken as part of the DiPEP study15 suggested that a clinical deci-
sion rule to avoid scanning in pregnant and postpartum women 
with suspected PE would need sensitivity >97.5% and specificity 
>90% to be cost- effective compared with a strategy of scanning 
for all.
CONCLUSION
We have shown that the combination of clinical probability 
assessment and D- dimer does not reliably rule out suspected PE 
in pregnancy. It is uncertain whether PE missed by these strate-
gies lead to clinically important consequences. Recent guidelines 
from the European Society for Cardiology and European Respi-
ratory Society15 suggest using clinical probability and D- dimer to 
rule out PE in pregnancy, based on the Righini and van der Pol 
studies. Our findings should be taken into account when consid-
ering these guidelines.
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